Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Checkmate Pharmaceuticals

Checkmate Pharmaceuticals
2015 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series B LATEST DEAL TYPE
$16M LATEST DEAL AMOUNT
5 INVESTORS
Description

Developer of cancer immunotherapies designed to recognize and destroy tumor cells. The company's immunotherapies offer knowledge in the field of CpG oligonucleotides and validate an approach that will combine the ability of CpG DNA to activate an anti-tumor T cell response with checkpoint inhibition to overcome a tumor's ability to mute the immune response, enabling patients to get new treatment options for cancer.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • 101 Main Street
  • 14th Floor
  • Cambridge, MA 02142
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Checkmate Pharmaceuticals’s full profile, request a free trial.

Checkmate Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 27-Jan-2020 $16M 0000 00000 Completed Generating Revenue
3. Early Stage VC (Series B) 12-Dec-2018 0000 0000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 02-Jun-2017 $27M $52M 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 16-Feb-2017 $25M $25M 0000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Checkmate Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Checkmate Pharmaceuticals Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Altor BioScience Formerly VC-backed Miramar, FL 00 00000 000000&0 00000
000000000 Venture Capital-Backed Rockville, MD 000.00 0000000000 0 000.00
000000000000 Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
0000000 00000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
00000000000 Angel-Backed Culver City, CA 00000 000000000000 00000
To view this company’s complete list of competitors, request access »

Checkmate Pharmaceuticals Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Decheng Capital Venture Capital Minority 000 0000 000000 0
Eight Roads Venture Capital Minority 000 0000 000000 0
F-Prime Capital Partners Venture Capital Minority 000 0000 000000 0
Sofinnova Investments Venture Capital Minority 000 0000 000000 0
venBio Venture Capital Minority 000 0000 000000 0

Checkmate Pharmaceuticals Executive Team (12)

Name Title Board
Seat
Contact
Info
Barry Labinger Chief Executive Officer, Board Member & President
Chuck Abdalian Chief Financial Officer
Karen Brennan Chief Operations Officer
Art Krieg MD Founder, Chief Scientific Officer & Board Member
Kleem Chaudhary Ph.D Chief Business Officer

2 Former Executives

You’re viewing 5 of 12 executives. Get the full list »

Checkmate Pharmaceuticals Board Members (6)

Name Representing Role Since Contact
Info
Alan Fuhrman Self Board Member 000 0000
Art Krieg MD Checkmate Pharmaceuticals Founder, Chief Scientific Officer & Board Member 000 0000
Ben Auspitz F-Prime Capital Partners Board Member 000 0000
Corey Goodman Ph.D venBio Board Member 000 0000
Keith Flaherty MD Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »